It is known that most patients with AML carrying FLT3-ITD show an initial favorable response to TKIs, such as midostaurin and gilteritinib; however, the emergence of drug-resistance can decrease drug efficacy [4]. Here, FLT3 is linked to acute myeloid leukemia.